{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T17:53:51Z","timestamp":1777053231386,"version":"3.51.4"},"reference-count":30,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,10,30]],"date-time":"2024-10-30T00:00:00Z","timestamp":1730246400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","jiac-j.com","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Infection and Chemotherapy"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.jiac.2024.10.012","type":"journal-article","created":{"date-parts":[[2024,10,22]],"date-time":"2024-10-22T07:28:29Z","timestamp":1729582109000},"page":"102544","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Effects of switching to dolutegravir\/lamivudine from tenofovir alafenamide fumarate\/emtricitabine\/dolutegravir or abacavir\/lamivudine\/dolutegravir on body weight and lipid profile in Japanese people living with HIV"],"prefix":"10.1016","volume":"31","author":[{"given":"Kenichi","family":"Ikegaya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6700-1791","authenticated-orcid":false,"given":"Takashi","family":"Muramatsu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1292-1707","authenticated-orcid":false,"given":"Ryoko","family":"Sekiya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Sekine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuko","family":"Harada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryui","family":"Miyashita","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Ichiki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yushi","family":"Chikasawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8716-8890","authenticated-orcid":false,"given":"Masato","family":"Bingo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5771-7190","authenticated-orcid":false,"given":"Mihoko","family":"Yotsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Hagiwara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kagehiro","family":"Amano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hironori","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ei","family":"Kinai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jiac.2024.10.012_bib1","doi-asserted-by":"crossref","first-page":"2398","DOI":"10.1073\/pnas.92.6.2398","article-title":"Emergence of human immunodeficiency virus type 1 variants with resistance to multiple dideoxynucleosides in patients receiving therapy with dideoxynucleosides","volume":"92","author":"Shirasaka","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jiac.2024.10.012_bib2","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1097\/QAD.0b013e32834bbaa9","article-title":"Efficacy of a nucleoside-sparing regimen of darunavir\/ritonavir plus raltegravir in treatment-naive HIV-1-infected patients (ACTG A5262)","volume":"25","author":"Taiwo","year":"2011","journal-title":"Aids"},{"key":"10.1016\/j.jiac.2024.10.012_bib3","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1007\/s40121-021-00522-7","article-title":"HIV Treatment with the two-drug regimen dolutegravir plus lamivudine in real-world clinical practice: a systematic literature review","volume":"10","author":"Patel","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jiac.2024.10.012_bib6","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1177\/2047487315579291","article-title":"An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: the Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study","volume":"23","author":"Friis-M\u00f8ller","year":"2016","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jiac.2024.10.012_bib7","doi-asserted-by":"crossref","first-page":"F17","DOI":"10.1097\/QAD.0b013e32830fe35e","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients","volume":"22","year":"2008","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.10.012_bib8","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1089\/aid.2022.0086","article-title":"Switching from tenofovir disoproxil to tenofovir alafenamide fumarate: impact on cardiovascular risk and lipid profile in people living with HIV, an observational study","volume":"39","author":"Moschopoulos","year":"2023","journal-title":"AIDS Res Hum Retrovir"},{"key":"10.1016\/j.jiac.2024.10.012_bib9","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/cid\/ciz999","article-title":"Weight gain following initiation of antiretroviral therapy: risk factors in randomized comparative clinical trials","volume":"71","author":"Sax","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib10","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/cid\/ciac036","volume":"75","author":"Osiyemi","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib11","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1111\/hiv.13432","article-title":"Change in metabolic parameters after switching from triple regimens with tenofovir alafenamide to dolutegravir-based dual therapy. Bi-lipid study","volume":"24","author":"Bendala-Estrada","year":"2023","journal-title":"HIV Med"},{"key":"10.1016\/j.jiac.2024.10.012_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1097\/QAI.0000000000002275","article-title":"Durable Efficacy of dolutegravir plus lamivudine in antiretroviral treatment-naive adults with HIV-1 infection: 96-week results from the GEMINI-1 and GEMINI-2 randomized clinical trials","volume":"83","author":"Cahn","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2024.10.012_bib13","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.jiac.2022.10.014","article-title":"Young age is a key determinant of body weight gain after switching from tenofovir disoproxil fumarate to tenofovir alafenamide in Japanese people living with HIV","volume":"29","author":"Sekiya","year":"2023","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.jiac.2024.10.012_bib14","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1093\/cid\/ciac130","volume":"76","author":"Llibre","year":"2023","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib15","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S0140-6736(18)32462-0","volume":"393","author":"Cahn","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2024.10.012_bib16","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0000000000002449","article-title":"Brief Report: durable suppression and low rate of virologic failure 3 years after switch to dolutegravir + rilpivirine 2-drug regimen: 148-week results from the SWORD-1 and SWORD-2 randomized clinical trials","volume":"85","author":"van Wyk","year":"2020","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2024.10.012_bib17","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(08)60423-7","article-title":"Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients enrolled in the D:A:D study: a multi-cohort collaboration","volume":"371","author":"Sabin","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.jiac.2024.10.012_bib18","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1093\/cid\/civ316","article-title":"Risk of cardiovascular events associated with current exposure to HIV antiretroviral therapies in a US veteran population","volume":"61","author":"Desai","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib19","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.ijantimicag.2018.07.010","article-title":"Risk of cardiovascular disease associated with exposure to abacavir among individuals with HIV: a systematic review and meta-analyses of results from 17 epidemiologic studies","volume":"52","author":"Dorjee","year":"2018","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jiac.2024.10.012_bib20","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1160\/TH09-08-0562","article-title":"Endothelium, venous thromboembolism and ischaemic cardiovascular events","volume":"103","author":"Gresele","year":"2010","journal-title":"Thromb Haemostasis"},{"key":"10.1016\/j.jiac.2024.10.012_bib21","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1097\/QAD.0b013e32834d3cc3","article-title":"Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase","volume":"25","author":"Baum","year":"2011","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.10.012_bib22","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1097\/QAD.0000000000001547","article-title":"Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation","volume":"31","author":"Alvarez","year":"2017","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.10.012_bib23","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1097\/QAI.0b013e31802bf122","article-title":"Less lipoatrophy and better lipid profile with abacavir as compared to stavudine: 96-week results of a randomized study","volume":"44","author":"Podzamczer","year":"2007","journal-title":"J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jiac.2024.10.012_bib24","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1097\/QAD.0000000000002151","article-title":"Associations between lipids and subclinical coronary atherosclerosis","volume":"33","author":"Whelton","year":"2019","journal-title":"AIDS"},{"key":"10.1016\/j.jiac.2024.10.012_bib25","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1186\/s12879-017-2626-z","article-title":"Cardiovascular risk and dyslipidemia among persons living with HIV: a review","volume":"17","author":"Maggi","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib26","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2024.10.012_bib27","doi-asserted-by":"crossref","first-page":"e666","DOI":"10.1016\/S2352-3018(20)30241-1","volume":"7","author":"Venter","year":"2020","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2024.10.012_bib28","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1016\/S2352-3018(18)30010-9","article-title":"Tenofovir alafenamide plus emtricitabine versus abacavir plus lamivudine for treatment of virologically suppressed HIV-1-infected adults: a randomised, double-blind, active-controlled, non-inferiority phase 3 trial","volume":"5","author":"Winston","year":"2018","journal-title":"Lancet HIV"},{"key":"10.1016\/j.jiac.2024.10.012_bib29","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1111\/j.1365-2125.2012.04440.x","article-title":"A phase 1 study to evaluate the effect of dolutegravir on renal function via measurement of iohexol and para-aminohippurate clearance in healthy subjects","volume":"75","author":"Koteff","year":"2013","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jiac.2024.10.012_bib30","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1093\/cid\/ciz1243","volume":"71","author":"van Wyk","year":"2020","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jiac.2024.10.012_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1177\/09564624221116530","article-title":"Accuracy of FIB-4 and APRI scores compared to transient elastography for liver fibrosis in patients with HIV and HBV co-infection","volume":"34","author":"Yang","year":"2023","journal-title":"Int J STD AIDS"},{"key":"10.1016\/j.jiac.2024.10.012_bib32","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofad359","article-title":"Cardiometabolic parameters 3 years after switch to dolutegravir\/lamivudine vs maintenance of tenofovir alafenamide-based regimens","volume":"10","author":"Batterham","year":"2023","journal-title":"Open Forum Infect Dis"}],"container-title":["Journal of Infection and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002915?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1341321X24002915?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T11:47:43Z","timestamp":1738928863000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1341321X24002915"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["S1341321X24002915"],"URL":"https:\/\/doi.org\/10.1016\/j.jiac.2024.10.012","relation":{},"ISSN":["1341-321X"],"issn-type":[{"value":"1341-321X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effects of switching to dolutegravir\/lamivudine from tenofovir alafenamide fumarate\/emtricitabine\/dolutegravir or abacavir\/lamivudine\/dolutegravir on body weight and lipid profile in Japanese people living with HIV","name":"articletitle","label":"Article Title"},{"value":"Journal of Infection and Chemotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jiac.2024.10.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Infection Prevention and Control. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102544"}}